U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07866430) titled 'De-EscaLaTion of Aromatase Inhibitor Therapy: A Randomized Phase II Study of De-escalated Letrozole in Hormone Receptor-Positive Early Breast Cancer' on Sept. 14.
Brief Summary: This study is a randomized, open-label, phase II trial designed to evaluate whether alternate-day dosing of letrozole preserves antiproliferative activity compared with standard daily dosing in postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Brest Cancer ER+ and HER2 Negative
Intervention:
DRUG: Letrozole
This study is designed as a non-inferiority tr...